Acorda Therapeutics, Inc.
ACOR
Rang in Aktien
#39163
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Aktienkurs
$0.879
Zuletzt synchronisiert: 2024-05-07
Marktkapitalisierung
$582.38K
Veränderung (1 Tag)
9.88%
Veränderung (1 Jahr)
8,690.00%
Land
US
Handel Acorda Therapeutics, Inc. (ACOR)
Kategorie
Healthcare
Gewinn für Acorda Therapeutics, Inc. (ACOR)
Gewinn im Mar 2024 TTM: $-304.44M
Laut den aktuellen Finanzberichten von Acorda Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $-304.44M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-35.25M, eine Steigerung gegenüber dem Gewinn im Jahr 2021, der $-109.07M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Acorda Therapeutics, Inc. von 2016 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-304.44M | 2.84% |
| 2023 | $-296.02M | 739.85% |
| 2022 | $-35.25M | -67.69% |
| 2021 | $-109.07M | 1.31% |
| 2020 | $-107.67M | -60.74% |
| 2019 | $-274.25M | -1,442.84% |
| 2018 | $20.42M | -108.11% |
| 2017 | $-251.89M | 495.92% |
| 2016 | $-42.27M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -679.61% |
IN
|
